VAXIMM AG

VAXIMM AG is a private, clinical stage, Swiss/German biotech developing oral T-cell immunotherapies against cancer. VAXIMM’s technology is based on first-in-class oral T-cell activators that can be readily adapted to target a wide range of cancer-related antigens. Lead product candidate VXM01 is designed to activate T-cells to attack the tumor vasculature, and, in several tumor types, attack cancer cells directly. VXM01 has orphan designation for the EU and the US for glioma.

VAXIMM’s neoantigen program is in preclinical development and has shown immune proof of concept; the Company’s platform allows for fast generation and delivery of personalized T-cell vaccines and may overcome key issues with other neoantigen approaches. A clinical Phase I basket study in collaboration with NEC is currently in preparation. Additional programs are in preclinical development.

 


VAXIMM AG at a glance:

 

Field of Activity
  • Oncology drug development
  • Oral T-cell immunotherapies
  • Neoantigens
  • COVID-19 program
Ownership Structure and Financing
  • Headquartered in Basel, Switzerland
  • Development activities are run from wholly owned subsidiary in Mannheim, Germany
  • Investors include: BB Biotech Ventures, BCM Europe, BioMed Partners, China Medical System Holdings, M Ventures, NEC and Sunstone Capital
Partners
  • Collaboration with Merck KGaA, Darmstadt, Germany, and Pfizer Inc. to evaluate VXM01 with avelumab
  • Development and collaboration agreement with CMS, granting CMS full rights in China and other Asian countries (excluding Japan) to VAXIMM’s oral T-cell immunotherapy programs
  • Clinical trial collaboration with NEC Corporation to develop personalized neoantigen cancer vaccines
Technology VAXIMM‘s plug and play technology is based on first-in-class oral T-cell activators that can be readily adapted to target a wide range of cancer-related antigens. The platform is based on the live attenuated bacterial vaccine strain Ty21, which has been administered to millions of people as a prophylactic vaccine to temporarily protect them from typhoid fever. This strain has been proven to be safe and well tolerated. All immunotherapies resulting from this platform are taken orally by the patient. The platform is suitable for addressing multiple targets with one treatment and can be combined with additional immunotherapies.
Date of Incorporation / Number of Employees 2008 / 10


Contact:

Dr. Heinz Lubenau – COO

 

Address Technologiepark Basel
Hochbergerstrasse 60c
4057 Basel
SwitzerlandOperations:
Harrlachweg 2
68163 Mannheim
Germany
Telephone/Telefax  +49 621-8359687-0/-99
E-Mail info@vaximm.com
Web Address www.vaximm.com
Social media LinkedIn Twitter